| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 09/12/2002 | US20020128271 N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| 09/12/2002 | US20020128270 Treating stroke, arhtritis, cancer, tissue ulceration, decubitis ulcer, restenosis, periodontal disease, epidermolysis bullosa, scleritis, psoriasis, AIDS, sepsis, and septic shock. |
| 09/12/2002 | US20020128265 CRF receptor antagonists and methods relating thereto |
| 09/12/2002 | US20020128240 Treatment of hyperproliferative diseases using active vitamin D analogues |
| 09/12/2002 | US20020128226 Enoxaparin and methods of its use |
| 09/12/2002 | US20020128225 Methods and products related to pulmonary delivery of polysaccharides |
| 09/12/2002 | US20020128202 Stimulation of bone growth with thrombin peptide derivatives |
| 09/12/2002 | US20020128178 Use of a growth hormone or a growth hormone secretagogue for promoting bone formation in an animal simultaneous with callus distraction |
| 09/12/2002 | US20020127694 2786, a novel human aminopeptidase |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127540 Detecting modulators of bone morphogenic activities; obtain cells, incubate with modulator, monitor expression of reporter molecules, compare to control |
| 09/12/2002 | DE10111877A1 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate New imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 09/12/2002 | CA2440803A1 Modulators of chemokine receptor activity |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439933A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | CA2439854A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 09/12/2002 | CA2439852A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 09/12/2002 | CA2439779A1 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | CA2439691A1 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | CA2439594A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | CA2439504A1 Compositions and methods relating to osteoarthritis |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1238075A2 Chordin-like molecules and uses thereof |
| 09/11/2002 | EP1238016A1 Substituted phthalocyanines and their precursors |
| 09/11/2002 | EP1237919A1 Interferon-alpha induced gene |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237878A2 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 09/11/2002 | EP1237877A2 Carboxamide-substituted benzimidazol derivatives, methods for the production thereof and their use as medicaments |
| 09/11/2002 | EP1237876A1 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses |
| 09/11/2002 | EP1237874A2 Selective neurokinin antagonists |
| 09/11/2002 | EP1237851A2 SALTS OF i Cis /i -4-CYANO-4- 3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| 09/11/2002 | EP1237845A1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/11/2002 | EP1237578A2 Micro-cluster liquids and methods of making and using them |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237568A1 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
| 09/11/2002 | EP1237560A2 Regenerative adjuvant (3-way tap) |
| 09/11/2002 | EP1237548A1 Il-8 receptor antagonists |
| 09/11/2002 | EP1237544A1 System and method for extended delivery of a therapeutic agent with its receptor loading dose |
| 09/11/2002 | EP1237539A1 Oral solution containing galanthamine and a sweetening agent |
| 09/11/2002 | EP0970047B1 2-alkylidene-19-nor-vitamin d compounds |
| 09/11/2002 | EP0958287B1 Sulfamide-metalloprotease inhibitors |
| 09/11/2002 | EP0813529B1 Arginine analogues having nitric oxide synthase inhibitor activity |
| 09/11/2002 | CN1369015A Recombinant anti-CD 40 antibody and uses thereof |
| 09/11/2002 | CN1369009A Modified chimeric polyeptides with improved pharmacokinetic properties |
| 09/11/2002 | CN1368970A Substituted 1,4-dihydroindeno [1,2-C] pyrazoles as inhibitors of tyrosine kinase |
| 09/11/2002 | CN1368963A Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/11/2002 | CN1368962A Fluorene derivatives |
| 09/11/2002 | CN1368961A Compounds for modulation of PPAP gamma activity |
| 09/11/2002 | CN1368958A Arylsulfonamido-substituted hydroxamic acid derivatives |
| 09/11/2002 | CN1368957A Aminobenzophenones as inhibiotors of IL-1 beta and TNF-alpha |
| 09/11/2002 | CN1368954A Salicylamide derivatives |
| 09/11/2002 | CN1368953A Aminobenzophenones as inhibitors of IL-1 bata and TNF-alpha |
| 09/11/2002 | CN1368950A Novel aminobenzophenones |
| 09/11/2002 | CN1368892A Sustained release formulation of peptide |
| 09/11/2002 | CN1368885A Compositions and methods for identifying antigens which elicit an immune response |
| 09/11/2002 | CN1368879A Use of (-)(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance type 2 diabetes, hyperlipidemia and hyperuricemia |
| 09/11/2002 | CN1368878A Drug therapy of restless leg syndrome |
| 09/11/2002 | CN1368382A Usage of hypophloeodal colyone and its application |
| 09/11/2002 | CN1368375A Composite medicine for treating osteoporosis |
| 09/11/2002 | CN1368373A Chinese medicine for treating bone tuberculosis, osteomyelitis, phlebitis and organism ulceration |
| 09/11/2002 | CN1368369A Medicine for treating algia disease and its preparing process |
| 09/11/2002 | CN1368365A Nano medicine 'Dinggongteng' and its preparing process |
| 09/11/2002 | CN1368363A Nano emdicine 'Yaoxitong' and its preparing process |
| 09/11/2002 | CN1368350A Nano medicine 'Gutongling' and its preparing process |
| 09/11/2002 | CN1368341A Nano medicine 'Pitong' and its preparing process |
| 09/11/2002 | CN1368308A Nano medicine for treating lumbago and its preparing process |
| 09/11/2002 | CN1368291A Nano anisodamine-musk medicine and its preparing process |
| 09/11/2002 | CN1368284A Nano medicine 'Shexiang Shuhuo' and its preparing process |
| 09/11/2002 | CN1368281A Nano medicine 'Zhuanggu' and its preparng process |
| 09/11/2002 | CN1368279A Nano medicine 'Zhuifeng Qiangshen' and its preparing process |
| 09/11/2002 | CN1368267A Nano snow lotus medicine and its preparing process |
| 09/11/2002 | CN1368260A Nano medicine 'Xiaoluotong' and its preparing process |
| 09/11/2002 | CN1368249A Nano medicine 'Dali' and its preparing process |
| 09/11/2002 | CN1368212A Nano medicine 'Shangtongning' and its preparing process |
| 09/11/2002 | CN1368191A Nano medicine 'Qufengshujin' and its preparing process |
| 09/11/2002 | CN1368184A Nano medicine 'Shujin Huoluo' and its preparing process |
| 09/11/2002 | CN1368181A Nano medicine 'Shufeng Dingtong' and its preparing process |
| 09/11/2002 | CN1368179A Nano medicine 'Shexiangqutong' and its preparing process |
| 09/11/2002 | CN1368146A Nano antalgic medicine for treating hyperosteogeny and its preparing process |
| 09/11/2002 | CN1368139A Nano medicine 'Huli' and its preparing process |
| 09/11/2002 | CN1368136A Nano medicine 'Shexiangzhenteng' and its preparing process |
| 09/11/2002 | CN1368125A Nano medicine 'Lajiaofengshi' and its preparing process |
| 09/11/2002 | CN1368064A Nano medicine 'yishenbugu' for tonifying kidney and strengthening bone and its preparing process |
| 09/11/2002 | CN1368063A Nano medicine 'Yushangling' and its preparing process |
| 09/11/2002 | CN1368055A Venine product for treating rheumatic and rheumatoid arthritis |
| 09/11/2002 | CN1090503C Medical capsule for treating rheumatism and building up body and its preparing process |
| 09/11/2002 | CN1090502C External use traditional Chinese medicinal for treating hyperosteogeny soft tissue injuries |